Teicoplanin
- PDF / 170,361 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 57 Downloads / 144 Views
1 S
Nephrotoxicity and hepatotoxicity: 49 case reports In a retrospective study of 512 patients, treated between June 2015 and May 2019, 49 patients (14 women and 35 men) aged 34–90 years were described, who developed nephrotoxicity or hepatotoxicity during treatment with teicoplanin for bacteraemia, methicillin-resistant Staphylococcus aureus (MRSA) infection, methicillin-sensitive Staphylococcus aureus (MSSA) infection, methicillin resistant coagulase-negative Staphylococci (MR-CNS) infection, Enterococcus faecalis infection, Enterococcus faecium infection, Enterococcus infection, gram-positive rod infection or Streptococcus infection [routes and times to reactions onsets not stated; not all outcomes stated]. Patients had underlying bacteraemia, MRSA, MSSA, MR-CNS, Enterococcus faecalis infection, Enterococcus faecium infection, Enterococcus infection, gram-positive rod infection or Streptococcus infection. In some of the patients, the infections manifested at blood-stream, respiratory-tract, intra-abdominal region, skin and soft-tissue region, urinary-tract region, or as osteomyelitis and arthritis. The patients received five doses of teicoplanin 10 mg/Kg or 12 mg/Kg loading dose for 3 days, administered twice daily on days 1 and 2, followed by once daily dose regimen on the third day. From day 4 onwards, this was followed by daily maintenance teicoplanin dose at 3.3–7.1 mg/Kg. Concomitant medications in few of these patients included total parenteral nutrition, unspecified corticosteroids, immunosuppressants or anti-cancer therapy. In some of these patients, investigations performed on day 4 of therapy revealed nephrotoxicity or hepatotoxicity, in whom, nephrotoxicity or hepatotoxicity were still evident towards the end of therapy. In the remaining patients, nephrotoxicity or hepatotoxicity were detected towards the end of therapy. The teicoplanin therapies were completed. Four of these 49 patients died eventually [immediate causes of death not stated]. Ueda T, et al. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 mug/mL using a regimen of 12 mg/kg for five doses 803501308 within the initial 3 days. BMC Pharmacology & Toxicology 21: No. 1, 2020. Available from: URL: http://doi.org/10.1186/s40360-020-00424-3
0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 19 Sep 2020 No. 1822
Data Loading...
